Table 2.
Antitumor effect of Abs, ADC and small molecule drugs on HER2 positive gastric cancer NCI-N87 cell xenografts.
| Mean tumor volume ±SD (mm3) |
||||||
|---|---|---|---|---|---|---|
| Groups | Route of administration and frequency | D0 | D21 | Tumor inhibition rate (%) | P value* | Observed tumor size on Day21 |
| Vehicle | iv, D0 | 98.2 ± 10.3 | 1167.7 ± 272.8 | — | — | |
| Hertuzumab-vcMMAE2.5 mg/kg | iv, D0 | 114.9 ± 12.7 | 76.9 ± 25.4 | 133 | abc | 6/6 PR |
| Hertuzumab-vcMMAE 5 mg/kg | iv, D0 | 107.4 ± 11.7 | 7.4 ± 18.2 | 193 | abc | 1/6 PR, 5/6 CR |
| Hertuzumab-vcMMAE10 mg/kg | iv, D0 | 109.0 ± 22.0 | 0.0 ± 0.0 | 200 | abc | 6/6 CR |
| Trastuzumab 10 mg/kg | iv, D0, 7, 14 | 112.3 ± 12.0 | 658.8 ± 210.4 | 49 | a | |
| Lapatinib 200 mg/kg | po, D0-20 | 102.4 ± 4.7 | 338.3 ± 79.7 | 78 | a | |
| Vehicle | iv, D0, 7 | 127.2 ± 15.7 | 1260.5 ± 404.6 | — | — | |
| Hertuzumab-vcMMAE0.5 mg/kg | iv, D0, 7 | 128.0 ± 16.7 | 1122.3 ± 289.5 | 12 | — | |
| Hertuzumab-vcMMAE5 mg/kg | iv, D0, 7 | 126.4 ± 26.6 | 0.0 ± 0.0 | 200 | ad | 6/6 CR |
| Hertuzumab5 mg/kg | iv, D0, 7 | 122.3 ± 9.2 | 1004.0 ± 344.4 | 22 | — | |
| MMAE 0.1 mg/kg | iv, D0, 7 | 121.7 ± 20.1 | 1013.2 ± 150.5 | 21 | — | |
| Hertuzumab 5 mg/kg + MMAE 0.1 mg/kg. | iv, D0, 7 | 131.2 ± 11.7 | 1089.4 ± 337.9 | 15 | — | |
D0 Days after random grouping
iv intravenous injection
Po intragastric administration
PR Tumor size was reduced compared to the vehicle group, but still observed
CR Tumors vanished completely
a
P<0.001 vs. Vehicle
b
P<0.001 vs. Trastuzumab
c
P<0.001 vs. Lapatinib
d
P<0.001 vs. Hertuzumab 5 mg/kg + MMAE 0.1 mg/kg
*
Student's t' test.